View in EDS HTML Full Text PDF Full Text

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer.

Saved in:
Bibliographic Details
Title: Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer.
Authors: Ma, Lingjun1 (AUTHOR), Zheng, Ran1 (AUTHOR), Xu, Lingyun2 (AUTHOR), Zhu, Ying3 (AUTHOR), Yin, Hong4 (AUTHOR), Zhang, Xiaoqing5 (AUTHOR), Deng, Rong3 (AUTHOR) dengrong1977@163.com, Wang, Jue1 (AUTHOR) wangjue200011@njmu.edu.cn, Zha, Xiaoming1 (AUTHOR) njzhaxm@njmu.edu.cn
Source: Cancer Research & Treatment. Apr2026, Vol. 58 Issue 2, p501-512. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:15982998
DOI:10.4143/crt.2024.1200